Pentacare Jan 2018 Quiz!!!!!!!!

20 Questions | By Balajimurugan33 | Updated: Feb 1, 2023 | Attempts: 128

Questions

Settings

Create your own Quiz

Questions and Answers

1.

Neurotransmitter is stored in:-
- A.
  
  Vessels
- B.
  
  Cell body
- C.
  
  Vesicles
- D.
  
  Nucleus
2.

Function of basal ganglia is __________
- A.
  
  Emotions
- B.
  
  Memory
- C.
  
  Motor coordination
- D.
  
  Language
3.

Process of breaking of tablets into small particles is called__________
- A.
  
  Absoprtion
- B.
  
  Disintegration
- C.
  
  Dissolution
- D.
  
  Metabolism
4.

The coverage strategy for Pentacare is
- A.
  
  20 doctors – 3 visits, 20 Doctors -1 visit and 60 doctors – 2 visits
- B.
  
  20 doctors – 4 visits, 20 Doctors -1 visit and 60 doctors – 2 visits
- C.
  
  20 doctors – 4 visits, 10 Doctors -1 visit and 70 doctors – 2 visits
- D.
  
  10 doctors – 4 visits, 30 Doctors -1 visit and 60 doctors – 2 visits
5.

If a tetra core doctor (4 Visit) is met 3 times in a month:
- A.
  
  He will be considered for total coverage
- B.
  
  He will not be considered for VF Coverage
- C.
  
  He well be considered for both Total Coverage and VF Coverage
- D.
  
  Both A & B
6.

If a Core doctor (2 Visit) is met 3 times in a month
- A.
  
  He will be considered for total coverage
- B.
  
  He will not be considered for VF Coverage
- C.
  
  He well be considered for both Total Coverage and VF Coverage
- D.
  
  He will not be considered for total coverage
7.

Unique Features of DONApp highlighted in VA are
- A.
  
  Patient tracker
- B.
  
  Know about Dementia & Alzheimers
- C.
  
  Appointment reminders
- D.
  
  Photo album
- E.
  
  All of the above
8.

Combination therapy of Donep – M /M forte provides greater improvement over monotherapy in terms of
- A.
  
  A. Cognitive functions
- B.
  
  B. Behavioural and Psychological Symptoms of dementia
- C.
  
  C. Global Functions
- D.
  
  D. All of the above
- E.
  
  E. Both B & C
9.

I remember dispenser contains
- A.
  
  A. PEL- containing information on personal hygiene
- B.
  
  B. PEL – containing information on personal hygiene and care of Dementia and Alzheimer’s patients
- C.
  
  C. Memory test
- D.
  
  D. Both B and C
10.

Donep plain & combination is targeted against which of the following specialities (As per cycle meet strategy)
- A.
  
  A. Donep M - Neurologists & Donep - Psychiatry
- B.
  
  B. Donep – Neuros & Donep M - Psychiatry
- C.
  
  C. Donep M – Neuro & Donep M - CPs
- D.
  
  D. None of the above
11.

Latest update in the facebook community was on which topic
- A.
  
  A. On father & son relationship
- B.
  
  B. On mother & daughter relationship
- C.
  
  C. Memories of childhood friendship
- D.
  
  D. Differences between old age symptoms Vs Dementia symptoms
12.

Identify the right indications which will suit Neurokem OD
- A.
  
  A. Maintainance phase of NeP
- B.
  
  B. Working class of patients with NeP
- C.
  
  C. Mild to moderate conditions of Nep
- D.
  
  D. All of the above
13.

If a CP sees about 20-25 patients/day and he is Rxers monthly 5 boxes of gabapentin. Can we select him to conduct NeP camp?
- A.
  
  Yes
- B.
  
  No
- C.
  
  Will think about it
- D.
  
  None of the above
14.

MRP of Neurokem OD is _________
- A.
  
  130 rupees/ Strips of 10 Tablets
- B.
  
  115 rupees/ Strips of 10 Tablets
- C.
  
  122 rupees/ Strips of 10 Tablets
- D.
  
  110 rupees/ Strips of 10 Tablets
15.

Targeted PMPM for Neurokem OD is
- A.
  
  25000
- B.
  
  20000
- C.
  
  30000
- D.
  
  15000
16.

The highlighting points of Valkem OD Video are
- A.
  
  All the points mentioned below
- B.
  
  OD tablets if broken doesn’t give 24 hour protection
- C.
  
  Patients prefer smaller, oval shaped and white tablets
- D.
  
  Valkem OD uses HPMC technology
- E.
  
  D. Alu-Alu packing doesn’t allow swelling of tablets due to moisture
17.

Which is not a benefit of Alu Alu Packing:
- A.
  
  A. Resistance from light and moisture
- B.
  
  B. Ensures stability during formulation
- C.
  
  C. No cavity
- D.
  
  D. Ensures stability post formulation
18.

Lacosamide ( Sizlac) is approved as monotherapy by European Medical Agency for
- A.
  
  A. POS in adults
- B.
  
  B. POS in children above 2 years of age, adults and adolescent
- C.
  
  C. POS in adolescent
- D.
  
  D. POS in adults, adolescent and children from 4 years of age
19.

The advantages of Lacosamide inj (Sizlac) in SE are
- A.
  
  Offers high response rate of 57% as a monotherapy
- B.
  
  Lack of drug-drug interaction potential
- C.
  
  Both the above
- D.
  
  None of the above
20.

MRP of Sizlac inj is _______
- A.
  
  203
- B.
  
  198
- C.
  
  183
- D.
  
  193